Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Lexicon Pharmaceuticals (LXRX) Accumulated Depreciation & Amortization (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $621000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 16.29% to $621000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $621000.0, a 16.29% increase, with the full-year FY2025 number at $621000.0, up 16.29% from a year prior.
  • Accumulated Depreciation & Amortization was $621000.0 for Q4 2025 at Lexicon Pharmaceuticals, up from $534000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $621000.0 in Q4 2025 to a low of $112000.0 in Q1 2023.
  • A 3-year average of $368888.9 and a median of $407000.0 in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest YoY gain for Accumulated Depreciation & Amortization was 28.57% in 2024; the steepest drop was 3.61% in 2024.
  • Lexicon Pharmaceuticals' Accumulated Depreciation & Amortization stood at $554000.0 in 2023, then fell by 3.61% to $534000.0 in 2024, then grew by 16.29% to $621000.0 in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Accumulated Depreciation & Amortization are $621000.0 (Q4 2025), $534000.0 (Q4 2024), and $409000.0 (Q3 2024).